• 2 March 2021
    Axonics® Announces Strategic Alliance for the Manufacture of New Non-Rechargeable Implantable Sacral Neuromodulation Device

    Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, today announced it has entered into a strategic alliance with Micro Systems Technologies (MST), a leading manufacturer of medical microelectronics. 

    MST currently manufactures printed circuit board assemblies for the Axonics r-SNM System in Lake Oswego, Oregon. This strategic alliance expands Axonics’ relationship with MST, with the parties collaborating on the non-rechargeable SNM device Axonics has developed and anticipates bringing to market following FDA approval.

    Raymond W. Cohen, chief executive officer of Axonics, commented, “We have been working with MST for over half a decade and we have developed a strong relationship. As Axonics develops new SNM embodiments for the benefit of patients suffering from bladder and bowel dysfunction, working with an experienced, best-in-class contract manufacturer with proven implantable device experience and the ability to rapidly scale is critical to support our long-term growth objectives.”

    The newly developed Axonics non-rechargeable implantable neurostimulator will be manufactured on the most advanced printed circuit board assembly line at Micro Systems Engineering, Inc., an MST company. The line leverages automation and an exceptional paperless traceability system to drive superior levels of throughput, yields and quality.

    Christian Roessle, president of sales and marketing at MST, commented, “MST is proud to broaden our relationship with Axonics and is committed to continuing to provide the highest quality medical components and automated manufacturing capabilities. Our extensive experience in microelectronics and implantable technology, as well as our specialization in the production of hundreds of thousands of implantable devices, positions MST to provide excellent support to Axonics for years to come.”